Stockscreener 앱 받기
23.12
1.81%
0.41
시장 영업 전:
23.24
0.12
+0.52%
전일 마감가:
$22.71
열려 있는:
$22.83
하루 거래량:
444.83K
Relative Volume:
0.25
시가총액:
$2.86B
수익:
$247.00M
순이익/손실:
$-249.00M
주가수익비율:
-7.4822
EPS:
-3.09
순현금흐름:
$-267.00M
1주 성능:
+3.77%
1개월 성능:
-0.26%
6개월 성능:
+164.23%
1년 성능:
+45.32%
1일 변동 폭
$22.53
$23.16
1주일 범위
$21.80
$23.49
52주 변동 폭
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
명칭
Arcus Biosciences Inc
전화
(510) 694-6200
주소
3928 POINT EDEN WAY, HAYWARD, CA
RCUS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
23.12 | 2.81B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-26 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | 개시 | H.C. Wainwright | Neutral |
| 2024-10-08 | 개시 | Wells Fargo | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-11-23 | 개시 | Evercore ISI | Outperform |
| 2020-04-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-09-27 | 개시 | Mizuho | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2018-10-09 | 개시 | Wedbush | Outperform |
| 2018-04-09 | 개시 | Citigroup | Buy |
| 2018-04-09 | 개시 | Goldman | Neutral |
| 2018-04-09 | 개시 | Leerink Partners | Outperform |
모두보기
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
Arcus Biosciences Earnings Notes - Trefis
Understanding Momentum Shifts in (RCUS) - news.stocktradersdaily.com
Can Arcus Biosciences Inc. stock deliver consistent earnings growthQuarterly Investment Review & Comprehensive Market Scan Reports - Улправда
Have Insiders Sold Arcus Biosciences Shares Recently? - simplywall.st
Squarepoint Ops LLC Boosts Stake in Arcus Biosciences, Inc. $RCUS - MarketBeat
Can Arcus Biosciences Inc. stock deliver sustainable ROEMarket Sentiment Report & Technical Confirmation Trade Alerts - Улправда
How higher bond yields impact Arcus Biosciences Inc. stockJuly 2025 Breakouts & Safe Entry Trade Signal Reports - ulpravda.ru
Is Arcus Biosciences Inc. stock attractive after correctionEarnings Growth Summary & Weekly Stock Performance Updates - Bölüm Sonu Canavarı
Market Outlook: Can Arcus Biosciences Inc. stock maintain operating marginsQuarterly Market Summary & Daily Entry Point Trade Alerts - DonanımHaber
Arcus Biosciences (NYSE:RCUS) Insider Richard Markus Sells 4,494 Shares - MarketBeat
Insider Selling: Arcus Biosciences (NYSE:RCUS) CAO Sells 2,113 Shares of Stock - MarketBeat
Carolyn Tang Sells 7,658 Shares of Arcus Biosciences (NYSE:RCUS) Stock - MarketBeat
Arcus Biosciences (NYSE:RCUS) President Sells $245,603.00 in Stock - MarketBeat
Richard Markus Sells 5,052 Shares of Arcus Biosciences (NYSE:RCUS) Stock - MarketBeat
Jennifer Jarrett Sells 9,983 Shares of Arcus Biosciences (NYSE:RCUS) Stock - MarketBeat
Arcus Biosciences (NYSE:RCUS) General Counsel Sells $150,909.60 in Stock - MarketBeat
Arcus Biosciences amends loan agreement, extends maturity and updates terms - Investing.com Nigeria
Arcus Biosciences Insider Sold Shares Worth $466,870, According to a Recent SEC Filing - marketscreener.com
Arcus Biosciences Insider Sold Shares Worth $278,739, According to a Recent SEC Filing - marketscreener.com
Arcus Biosciences Insider Sold Shares Worth $318,496, According to a Recent SEC Filing - marketscreener.com
Arcus Biosciences Executives Sell Shares to Cover Tax Obligations - TradingView — Track All Markets
Officer Azoy Sells 4,343 ($96.6K) Of Arcus Biosciences Inc [RCUS] - TradingView — Track All Markets
[Form 4] Arcus Biosciences, Inc. Insider Trading Activity - Stock Titan
Arcus Biosciences Amends Loan Facility, Extends Maturity Terms - TipRanks
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Cancer-focused Arcus Biosciences to present at major health conference - Stock Titan
February 2026 Options Now Available For Arcus Biosciences (RCUS) - Nasdaq
Arcus Biosciences amends loan facility, extends maturity terms - MSN
Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221 (NYSE:RCUS) - Seeking Alpha
This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell? - Barchart.com
Officer Markus Files To Sell 10,000 Of Arcus Biosciences Inc [RCUS] - TradingView — Track All Markets
Pres Jaen Files To Sell 22,000 Of Arcus Biosciences Inc [RCUS] - TradingView — Track All Markets
Arcus Biosciences (NYSE: RCUS) shareholder files Rule 144 to sell 5,000 shares - Stock Titan
RCUS Stock Down on Decision to Discontinue GILD Partnered Study - Finviz
Arcus Biosciences stock price target raised to $32 at H.C. Wainwright - Investing.com Canada
Domvanalimab failure bad news for Arcus and TIGIT class - The Pharma Letter
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Assessing Arcus Biosciences’ Valuation After Halting Key GI Trials and Pivoting to Casdatifan-Focused Strategy - simplywall.st
Arcus Biosciences (RCUS) Stock News, Forecasts and Analyst Targets — Dec. 14, 2025 Update - ts2.tech
Why Arcus Biosciences (RCUS) Is Down 15.4% After Halting Key Domvanalimab Cancer Trials And What's Next - Yahoo Finance
Arcus Biosciences (NYSE:RCUS) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Arcus Biosciences (NYSE:RCUS) Shares Gap DownHere's What Happened - MarketBeat
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $32.00 at HC Wainwright - MarketBeat
Arcus Biosciences Target of Unusually Large Options Trading (NYSE:RCUS) - MarketBeat
Gilead, Arcus scrap late-stage trial of cancer drug combo - wtvbam.com
Why Arcus Biosciences just reversed its 287% eight-month winning streak - MSN
HC Wainwright & Co. Maintains Arcus Biosciences (RCUS) Buy Recommendation - Nasdaq
Arcus Calls Quits On Anti-TIGIT Candidate After Phase III Termination - Citeline News & Insights
Arcus shifts effort, bears down on would-be ‘anchor’ in RCC - BioWorld MedTech
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug - Benzinga
H.C. Wainwright raises Arcus Biosciences stock price target to $32 on lower expenses - Investing.com Canada
Arcus Biosciences Inc (RCUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
0.21%
자본화:
|
볼륨(24시간):